Difference between revisions of "Team:TCU Taiwan/Modeling/Protein structure"

 
(10 intermediate revisions by 2 users not shown)
Line 14: Line 14:
 
  overflow: auto;
 
  overflow: auto;
 
  margin: 1.2em auto 0;
 
  margin: 1.2em auto 0;
−
  text-align: justify;
+
  text-align: left;
 
  border:0px;
 
  border:0px;
 
  border-right:none;
 
  border-right:none;
Line 42: Line 42:
 
  <div class="inner">
 
  <div class="inner">
 
<table width="95%"  align="center">
 
<table width="95%"  align="center">
−
<h1>
+
 
−
<tr><td align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> About our modeling</font></span></td></tr><tr><td><span style="font-family:Calibri;text-align:justify;"><font size="5"></br></br>為了能夠使我們更有效地拿到我們的指定抗菌肽，我們在設計序列時在AMPs的N-terminal加上了來自S.lividans幾丁質酶C的signal peptide (附上氨基酸序列)。這個pre-mature peptide在經過periplasmic space時會被peptidase辨認並且做切割。Peptidase會辨認signal peptide 上Ala-Gln-Ala序列，並且從signal和mature peptide中間的兩個Ala間將之分開。為了使peptidase能夠順利辨認並且切割，我們在AMP的N-terminal多加了一個Ala氨基酸，以確保整個系統能順利運作。
+
<tr><td align="justify" ><h1><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> About our modeling</font></span></h1></td></tr>
−
我們利用模擬技術，利用原本的已知結構，去推測在我們多加了一個Ala的情況下，是否會影響AMPs的蛋白結構折疊。
+
<tr><td><h1><span style="font-family:Calibri;text-align:left;"><font size="5">
 +
To increase efficiency in isolating our AMPs, we introduced a signal peptide upstream of the N-terminal of our AMPs. This signal peptide is obtained from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). When the fusion peptides enter the periplasmic space, peptidase will identify the cleavage site Ala-Gln-Ala and cut at the double Ala between the signal and AMPs. </br></br>
 +
To ensure and verify this process, we have attached an Ala at the N-terminal of AMPs. When applying a protein secondary structure prediction software base on the known peptide structure, we can analyze whether the attached Ala may have an effect on the peptide folding process.
 
</br></br>
 
</br></br>
 +
</font></span></h1></td>
 +
  </tr>
 +
</table>
 +
</div>
 +
</div>
  
−
In order to have more efficient to get our AMPs, we treated signal peptide upstream of the N-terminal of mature antimicrobial peptides. This signal peptide is comes from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). When the pre-mature peptides go through the periplasmic space, peptidase will identified the cleavage site Ala-Gln-Ala and cut at the double Ala between the signal and mature peptide. </br></br>
+
<div id="st1" class="st">
−
To make sure the secretion system is work we attach an Ala at the N-terminal of AMPs. We used protein secondary structure prediction software base on the known peptide structure to analysis whether the attached Ala affect the peptide folding process or not.
+
<div class="inner">
 +
<table width="95%"  align="center">
 +
<tr><td align="left"><h1><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> Signiferin peptide structure analysis</font></span></h1></td></tr>
 +
  <tr>
 +
    <td width="90%" align="center"><img src="https://static.igem.org/mediawiki/2015/e/ee/2015tcutaiwanModelingwithoutA1.jpg" align=center width="80%"  title="Result 1"></td>
 +
  </tr> 
 +
</table>
 +
</div>
 +
</div>
 +
 
 +
<div id="st1" class="st">
 +
<div class="inner">
 +
<table width="95%"  align="center">
 +
 
 +
    <td width="45%" align="center"><img src="https://static.igem.org/mediawiki/2015/f/f8/2015tcutaiwanModelingwithA1.jpg" align=center width="80%"  title="Result 1"></td>
 +
  </tr> 
 +
</table>
 +
</div>
 +
</div>
 +
 
 +
<div id="st1" class="st">
 +
<div class="inner">
 +
<table width="95%"  align="center">
 +
<tr><td><h1><span style="font-family:Calibri;text-align:justify;"><font size="5"></br>
 +
The first column shows the amino acid sequence that we predict.
 +
The second column shows that AMPs corresponding secondary structure state are still a-helix.
 +
The third column shows the probability of correct prediction.
 
</br></br>
 
</br></br>
−
</font></span></td>
+
</font></span></h1></td></tr>  
−
  </tr></h1>
+
 
</table>
 
</table>
 
</div>
 
</div>
Line 60: Line 92:
 
<table width="95%"  align="center">
 
<table width="95%"  align="center">
 
   <tr>
 
   <tr>
−
    <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/1/17/2015tcutaiwanmodelingsigaddA.JPG" align=center width="80%"  title="with amino acid A"></td>
+
<tr><td align="left"><h1><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> Epinicedin-1 pepetide structure analysis</font></span></h1></td></tr>
−
    <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> with Ala attach </br>N-terminal</br></font></span><img src="https://static.igem.org/mediawiki/2015/2/2a/2015tcutaiwanmodelingdataSigaddA.JPG" align=center width="72%"  title="Result 1"></td>
+
  <tr>
 +
  <td width="45%" align="center"><img src="https://static.igem.org/mediawiki/2015/8/82/2015tcutaiwanModelingepi-1withoutA1.jpg" align=center width="80%"  title="Result 4"></td>
 
   </tr>   
 
   </tr>   
 
</table>
 
</table>
Line 71: Line 104:
 
<table width="95%"  align="center">
 
<table width="95%"  align="center">
 
   <tr>
 
   <tr>
−
<td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/6/67/2015tcutaiwanmodelingsigwithoutA.JPG" align=center width="80%"  title="without amino acid A"></td>
+
<td width="90%" align="center"><img src="https://static.igem.org/mediawiki/2015/1/10/2015tcutaiwanigemModelingepi-1withA1.jpg" align=center width="80%"  title="Result 3"></td>
−
     <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> without Ala attach </br>N-terminal</br><img src="https://static.igem.org/mediawiki/2015/1/12/2015tcutaiwanmodelingdataSigwithoutA.JPG" align=center width="72%"  title="Result 2"></font></span></td>
+
      
−
  </tr>  </table>
+
  </tr>  
 +
</table>
 +
</div>
 +
</div>
 +
 
 +
<div id="st1" class="st">
 +
  <div class="inner">
 
<table width="95%"  align="center">
 
<table width="95%"  align="center">
−
<tr><td ><span style="font-family:Calibri;text-align:justify;"><font size="5">The first column shows the amino acid sequence we predict.
+
<tr><td><h1><span style="font-family:Calibri;text-align:justify;"><font size="5"></br>
 +
The first column shows the amino acid sequence that we predict.
 
The second column shows that AMPs corresponding secondary structure state are still a-helix.  
 
The second column shows that AMPs corresponding secondary structure state are still a-helix.  
 
The third column shows the probability of correct prediction.
 
The third column shows the probability of correct prediction.
−
</font></span>
+
</br></br>
−
</td></tr>
+
</font></span></h1></td></tr>  
 
</table>
 
</table>
 
</div>
 
</div>
 
</div>
 
</div>
 +
  
 
<div id="st1" class="st">
 
<div id="st1" class="st">
 
  <div class="inner">
 
  <div class="inner">
 
<table width="95%"  align="center">
 
<table width="95%"  align="center">
−
<h1>
 
−
<tr><td align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> Conclusion</font></span></td><td></tr><tr><span style="font-family:Calibri;text-align:justify;"><font size="5"></br></br>Signiferin以及Epinicidin-1都是由 a helix結構所構成，在我們的模擬分析後，不管是signiferin還是Epinecidin-1在N-terminal多加了一個Ala後並不影響蛋白的摺疊結構。</br></br>
 
  
−
Through the secondary structure predicted. The result shows whatever Signiferin or Epinecidin-1 the attached of Ala didn’t affect peptide-folding process. They are still a-helix structure.
+
<tr><td align="center"><h1><span style="font-family:Arial Black;"><font size="7"><font-weight: 700;> Conclusion</font></span></h1></td></tr>
 +
<tr><td><h1><span style="font-family:Calibri;text-align:justify;"><font size="5"></br>
 +
Through the analysis of the peptide secondary structure and confirmation of the -helix structure, the results show whether Ala is attached to Signiferin or Epinecidin-1, the peptide did not affect the peptide folding process. process.
 
</br></br>
 
</br></br>
−
</font></span></td>
+
</font></span></h1></td></tr>  
−
  </tr></h1>
+
 
</table>
 
</table>
 
</div>
 
</div>

Latest revision as of 16:38, 18 September 2015

About our modeling

To increase efficiency in isolating our AMPs, we introduced a signal peptide upstream of the N-terminal of our AMPs. This signal peptide is obtained from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). When the fusion peptides enter the periplasmic space, peptidase will identify the cleavage site Ala-Gln-Ala and cut at the double Ala between the signal and AMPs.

To ensure and verify this process, we have attached an Ala at the N-terminal of AMPs. When applying a protein secondary structure prediction software base on the known peptide structure, we can analyze whether the attached Ala may have an effect on the peptide folding process.

Signiferin peptide structure analysis


The first column shows the amino acid sequence that we predict. The second column shows that AMPs corresponding secondary structure state are still a-helix. The third column shows the probability of correct prediction.

Epinicedin-1 pepetide structure analysis


The first column shows the amino acid sequence that we predict. The second column shows that AMPs corresponding secondary structure state are still a-helix. The third column shows the probability of correct prediction.

Conclusion


Through the analysis of the peptide secondary structure and confirmation of the -helix structure, the results show whether Ala is attached to Signiferin or Epinecidin-1, the peptide did not affect the peptide folding process. process.



             
Flag Counter
Contact us
 tcutaiwan@gmail.com
No.701, Sec. 3, Zhongyang Rd. Hualien 97004, Taiwan